• If you are wondering whether Collegium Pharmaceutical's current share price reflects its real worth, this breakdown will help you see what the numbers are actually saying about value.
• The stock closed at US$33.42, with returns of 13.1% over 1 year and 37.1% over 3 years, but a 26.0% decline over 30 days and 26.6% decline year to date may have changed how investors think about its risk and reward profile.
• Recent coverage has focused on Collegium Pharmaceutical in the context of its share price performance, with attention on how the pullback over the past month compares with its positive multi year returns. This mix of shorter term weakness and longer term gains has raised questions about whether the current price offers value or signals caution.
• On Simply Wall St's 6 point valuation checklist, Collegium Pharmaceutical scores a 5 out of 6, and the sections ahead will walk through the different valuation methods behind that score and point to a more complete way to think about value at the end of the article.

Approach 1: Collegium Pharmaceutical Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a company might be worth by projecting its future cash flows and discounting them back to today using a required rate of return. In this case, the model used is a 2 Stage Free Cash Flow to Equity approach based on cash flow projections.

Collegium Pharmaceutical is shown with last twelve month free cash flow of about $327.8 million. Analyst inputs and extrapolations point to projected free cash flow of $277.5 million in 2030, with annual figures between 2026 and 2035 ranging from about $260 million to $347.7 million, according to the provided ten year projections.

Bringing all those future cash flows back to today, Simply Wall St’s model arrives at an estimated intrinsic value of $187.83 per share. Compared with the recent share price of $33.42, the DCF output implies the stock is 82.2% undervalued based on these assumptions and inputs.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Collegium Pharmaceutical is undervalued by 82.2%. Track this in your watchlist or portfolio, or discover 61 more high quality undervalued stocks.

Approach 2: Collegium Pharmaceutical Price vs Earnings

For a profitable company, the P/E ratio is a useful yardstick because it links what you pay per share to the earnings that support that price. Investors usually accept a higher or lower P/E depending on what they expect for future growth and how much risk they see in those earnings. Higher growth and lower perceived risk can justify a higher P/E, while lower growth or higher risk often call for a lower multiple.

Collegium Pharmaceutical currently trades on a P/E of 16.88x. That is in line with the Pharmaceuticals industry average of about 16.88x and sits below the peer group average of 39.85x. Simply Wall St also calculates a “Fair Ratio” of 23.15x, which is the P/E that would typically be expected given factors like the company’s earnings growth profile, profit margins, industry, market cap and specific risks.

This Fair Ratio is more tailored than a simple comparison to peers or the broad industry because it adjusts for company specific characteristics instead of assuming all drug makers deserve the same multiple. Comparing the actual P/E of 16.88x with the Fair Ratio of 23.15x indicates that the shares are trading below that modelled level.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Collegium Pharmaceutical Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St’s Community page let you connect your view of Collegium Pharmaceutical’s story to a specific forecast and fair value, then compare that fair value with today’s price to help inform decisions. The narrative and its valuation update automatically when new earnings or news arrive. This is why one investor might build a more optimistic Collegium Narrative around the higher US$60.00 analyst target, while another leans on the more cautious US$44.00 target. Both can clearly see how their own revenue, earnings and margin assumptions translate into different fair values for the same stock.

Do you think there's more to the story for Collegium Pharmaceutical? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.